BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36045701)

  • 1. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A; Haber PK; Sia D
    JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapies for Perihilar Cholangiocarcinoma.
    Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat biliary tract cancer.
    Lamarca A; Edeline J; Goyal L
    ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
    Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
    Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
    Rizzo A; Tavolari S; Ricci AD; Frega G; Palloni A; Relli V; Salati M; Fenocchio E; Massa A; Aglietta M; Brandi G
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
    Malenica I; Donadon M; Lleo A
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
    Chakrabarti S; Kamgar M; Mahipal A
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Oncology Targets in Biliary Tract Cancer.
    Farha N; Dima D; Ullah F; Kamath S
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
    Personeni N; Lleo A; Pressiani T; Colapietro F; Openshaw MR; Stavraka C; Pouptsis A; Pinato DJ; Rimassa L
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.